Potential blockbuster drugs to watch in 2023

Science's 2023 Breakthrough of the Year: Weight loss drugs with a ...

Obesity meets its match. Blockbuster weight loss drugs show promise for a wider range of health benefits ... potential, but some scientists ...

13 Potential Blockbuster Drugs and Gamechangers to Watch in 2024

– Clarivate Plc, a provider of trusted information and insights, today unveiled its highly anticipated 2024 Drugs to Watch report, shining a ...

Top 10 Biopharma Takeover Targets of 2024

BMS was very busy in Q4 2023, as it also announced plans to buy out radiopharmaceutical drug developer RayzeBio and oncology drug developer ...

5 Pharmaceutical Stocks With Blockbuster Drugs in the Pipeline

A more immediate blockbuster drug prospect for AZN is Imfinzi. Imfinzi, more formally known as durvalumab, blocks certain proteins which allow a ...

Most significant clinical trials of 2023

From the first success in a Phase III CRISPR trial to another Alzheimer's disease drug showing efficacy in disease progression, 2023 has been a notable year ...

Biotherapeutics: Hotly Anticipated Blockbuster Drugs in the Pipeline

... potentially become a $1 billion drug ... The US will have to wait until 2023 for a generic of the hugely successful blockbuster to hit their ...

Blockbuster Drugs: The Rise and Fall of the Pharmaceutical Industry

However, blockbuster drugs for biologics are on the rise. Enbrel, Humira, Remicade, Avastin, and others are now all the rage. Most big pharmaceutical companies ...

Azurity Wins FDA Approval for Oral CML Drug - BioSpace

In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.

Blockbuster diabetes drug earns heart indication - Formulary Watch

Blockbuster diabetes drug earns heart indication · Rigel Warns Physicians About Fatal Infections from Gavreto · FDA Approves IV Form of Stelara ...

New Drug Modalities Offer Promise and Peril

A wave of innovation in oncology is bringing on new drug modalities with potential to create value. Read more to find out what the benefits ...

7 Drug Stocks That Will Soar in 2023 - Yahoo Finance

Let's take a look at some drug stocks to buy. These names look very well-positioned to generate large profits for investors in 2023 and in subsequent years.

The two-horse race to make blockbuster obesity drugs - Axios

Other pharma giants such as Pfizer, Merck and Amgen are trying to gain a foothold with their own drug candidates, as are smaller biotechs like ...

1. AACR Orlando 2023: New Drug Candidates - The AACR first disclosures presented in the Chemistry in Cancer Research's “New Drugs on the Horizon ...

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?

Last December, Pfizer formed a new company with Roivant Sciences to trial an experimental IBD medication. · The therapy sports a novel mechanism ...

Top Industry Trends for Manufacturers to Watch in 2023 - BioCare, Inc.

This year, trending developments range from AI cementing its role in drug development to potential price wars cropping up in the wake of the ...

Pipelines Report 2023: innovation and diversification - PharmaLive

Clarivate's Drugs to Watch 2023 list identified ritlecitinib as one of 15 late-stage experimental treatments that are each forecast to deliver ...

Pipelines Report 2024: M&A and AI Momentum - Model N

Clarivate identified 13 potential blockbuster drugs and game changers in the company's annual drugs to watch report for 2024, including Casgevy. “All eyes ...

10 biotech companies to watch in 2023 - Labiotech

ArgenxBack to Top ... As biotech stock markets continued to stagnate in 2022, Argenx was one of the few biotech companies whose stock price ...

10 Blockbuster Drugs of the Future | Kiplinger

Verzenio Eli Lilly; Treats: Breast cancer · Epacadostat Epacadostat Incyte; Treats: Lung cancer · Semaglutide Novo Nordisk; Treats: Diabetes.

In the Pipeline: Top Drug Candidates for FDA Approval in 2024

In 2023, the United States Food and Drug Administration ... potential of three notable treatments, all of which were approved during 2023.